Biophan - Super news - 500 Beiträge pro Seite

[SundP]

12:00 16Jul2004 BSW-Biophan Technologies Files 10-QSB for First Quarter of Fiscal 2005; <BIPH.OB>

Biophan Technologies Files 10-QSB
for First Quarter of Fiscal 2005; Company Discloses Negotiations for
Potential Strategic Relationships and Licensing Agreements
ROCHESTER, N.Y.--(BUSINESS WIRE)--July 16, 2004--Biophan
Technologies, Inc. (OTC BB: BIPH), a leading developer of
next-generation biomedical technology, today announced the filing of
the Company`s 10-QSB for the first quarter of fiscal 2005.
"Our progress over the last quarter has been significant," stated
Michael Weiner, Biophan`s CEO. "This progress is underscored by the
continued implementation of Biophan`s strategic vision and evidenced
by a discussion of potential strategic relationships and licensing
agreements. Specifically, within the body of the 10-QSB filing for the
period ended May 31, 2004, we stated `An additional factor influencing
our decision to exercise all or part of the remaining SBI financing
involves negotiations with several biomedical device and
pharmaceutical companies, which may involve a combination of R&D
development and/or licensing payments, as well as a strategic
investment in equity in our company. Such an investment, should it
occur, may resolve, in whole or in part, our capital requirements for
listing on a major stock exchange, as well as providing us with
working capital to continue our research, and possible milestone
payments. As a result, we intend to be prudent in our exercise of the
SBI line, even with its very attractive fixed price aspects`."
Mr. Weiner also noted, "The Company is very pleased with the
additional patents which were noted in our release of July 7, 2004,
disclosing that Biophan now owns or has an exclusive license to a
total of 74 patents, of which 14 are issued, 6 are allowed, and 54 are
pending. Our stockholders should be pleased to know that Biophan, in
its aggressive commitment to stockholder growth, continues to explore
significant opportunities through multiple markets with multiple
products. In addition, Biophan continues to develop relationships and
negotiate strategic alliances with multiple, substantial parties."
Mr. Weiner concluded by noting, "In addition to the above positive
developments, in this last quarter Biophan also acquired an interest
in a patented biothermal battery technology and distribution rights
for a unique MRI-safe ceramic motor. Both have been extremely well
received and offer exciting potential upside for Biophan, its
strategic partners, customers, and stockholders."
On June 3, 2004, Biophan acquired a 51% interest in TE Bio LLC, a
company developing an implantable biothermal battery using body heat
gradients to power medical devices such as pacemakers, defibrillators,
and drug pumps. The biothermal battery technology is based on a
patented innovation in the utilization of thermoelectric materials,
using nanoscale-based, thin-film materials to convert thermal energy
produced naturally by the human body into electrical energy. The
resulting power can be used to "trickle charge" batteries for
medium-power devices such as defibrillators, or directly power
low-energy devices like pacemakers. It is enabled by nanotechnology
which provides the ability to put thousands and thousands of small
semi-conductor nodes that convert heat to electricity in a space about
the size of one or two postage stamps. Biophan presented the
technology at the NASPE Heart Rhythm Society meeting in San Francisco
earlier this year and received substantial industry interest from
major device manufacturers. The Company has recruited several
consultants experienced in this technology to assist in development.
Also, on June 4, 2004, Biophan announced that it had acquired from
New Scale Technologies, Inc. the exclusive worldwide distribution
rights for the medical market, including the multi-billion dollar drug
delivery market, for New Scale`s ceramic "SQUIGGLE(TM) motor."
Developed to meet the growing demand for high precision, low cost
actuation devices, the motor is currently on the market generating
revenues and is available for OEM integration today. The motor uses no
metal wire windings (one of the primary causes of image interference
under MRI), is capable of both linear and rotational movement, and can
move forward and backwards several inches at nanometer increments,
thereby providing a controllable drug release environment.
Most recently, at the annual stockholders` meeting on July 13,
2004, the Company disclosed additional details of its controllable
drug eluting technology, enabled by its nanomagnetic particle
technology. Presentations from the annual meeting can be viewed at
http://www.biophan.com/2004.php.
About Biophan Technologies
Biophan Technologies develops and markets cutting-edge
technologies designed to make biomedical devices safe and compatible
with magnetic resonance imaging (MRI) equipment. The Company develops
enabling technologies for implanted medical systems such as
pacemakers, and interventional surgical devices such as catheters and
guidewires, as well as stents and other implants that can be safely
and effectively imaged under MRI. The technology is also being used to
create enhanced MRI contrast agents. Committed to growth through
innovation and developmental leadership, Biophan and its licensors
have fourteen issued U.S. patents and over sixty patents pending, in
areas including nanotechnology (nanomagnetic particle coatings), radio
frequency filters, polymer composites, biothermal batteries, and
photonics. Biophan`s technology will help realize its goal of one day
making all biomedical devices capable of safely and successfully
working with MRI. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute
forward-looking statements. Actual results could differ materially
from such statements expressed or implied herein as a result of a
variety of factors including, but not limited to: the development of
Biophan`s technologies; the approval of Biophan`s patent applications;
the successful implementation of Biophan`s research and development
programs; the acceptance by the market of Biophan`s products;
competition and the timing of projects and trends in future operating
performance, as well as other factors expressed from time to time in
Biophan`s periodic filings with the Securities and Exchange Commission
(the "SEC"). As a result, this press release should be read in
conjunction with Biophan`s periodic filings with the SEC. The
forward-looking statements contained herein are made only as of the
date of this press release, and Biophan undertakes no obligation to
publicly update such forward-looking statements to reflect subsequent
events or circumstances.

[BullAG]

soll heißen, dass sie ihr medikament anfang 2005 durchbringen, oder?

bei dieser meldung sollte die aktie anspringen, wenns auch nur 10-oder 20 % werden,

[THUM]

ENDLICH WIEDER LAND IN SICHT, HABE GEDACHT ICH HAETTE EINEN STERBENDEN SCHWAN IM DEPOT.
MEINE PROGNOSE IN EINER HALBEN STUNDE WIEDER BEI 0,70 EURO UND AB GEHT`S.

THUM

[BullAG]

da sehen wir mehr als nur 0,70,

gebe meine stücke nicht unter 0,83

[trickygirl]

Dann wissen wir ja jetzt endlich, warum die MMs das Teil gestern nochmal in den Keller geschickt haben

[BullAG]

sind schon 2 cent hoch, bin gespannt wo wir schließen

[THUM]

WAS MEINST DU MIT MMs. ICH DENKE EHER, DAS WAREN ALTAKTIONAERE, DIE NACH DER HV WIDER STUECKE VERKAUFEN DUERFEN UND AUS DER SPERRFRIST DRAUSSEN SIND.

THUM

[trickygirl]

MMs sind "Marktmanipulatoren" in US

[unic]

Biophan Technologies erzielt positive Studienergebnisse

Die Biophan Technologies Inc. veröffentlichte heute Details einer neuen Studie über die Sicherheit von Herzschrittmachern.

Demnach erwärmt sich der Anschluss eines Standardschrittmachers in einem Standardmodell eines Kernspintomographen weit über die von der FDA festgesetzten, zulässigen oberen Temperaturgrenze. Die Studie zeigt, dass die Erwärmung nicht im Schrittmacherkabel, sondern an der Berührungsstelle zwischen Elektrode und Herz auftritt, wo sie eine signifikante Verletzung von Herzgewebe auslösen kann und schließlich den sicheren Betrieb des Schrittmachers verhindert.

Eine Untersuchung einiger Lösungen von Biophan ergab, dass ein HF-Filters die Erwärmung konstant und unter allen getesteten Kernspinbedingungen auf die FDA-Grenzwerte reduzierte. Biophan Technologies entwickelt und vermarktet Technologien, mit deren Hilfe sich biomedizinische Geräte, beispielsweise Herzschrittmacher und chirurgische und diagnostische Instrumente, sicher und problemlos mit Kernspintomografieausrüstungen betreiben lassen.

Bisher stiegen die Aktien um 0,99 Prozent und stehen derzeit bei 1,02 Euro.

Quelle: FINANZEN.NET
Also schon meinem Opa zuliebe behalte ich die Teile!Der hat momentan genau dieses Problem das er mit seinem Herzschrittmacher Probleme mit seine Krebstherapie bzw. Diagnostik bekommt!Kaufe was du verstehst sagte schon der alte Kosto und nun verstehe ich nochmehr wie wichtig und gebraucht ein solches Verfahren wäre!Man sollte wirklich nicht jeden Tag nach dem Kurs schauen sondern einfach liegen lassen(ist auch noch eine "humane" Aktie

[BillTylor]

Hallo zusammen,

hat jemand Infos über den letzten Rückgang
von Biophan? Bin gerade aus dem Urlaub zurück!!!!!!

Danke!!!!

[fritzchenI]

das ist der Grösste Flop aller zeiten-die aktie fällt nicht umsonst täglich 10 %- Unternehmens mitglieder,altaktionäre sind wohl schon raus wies aussieht-
so wies abgeht wirds vollends ein Totalverlust-bin mir sicher wir sehen die Aktie dieses Jahr noch bei 5 cent
ala augrid und sonstigen Frick -Aktien

[Mr.Perfect]

@fritzchen

nicht spieler maul halten!

bei biph nützt ein frick-push nichts! ist ein OTC`ler und die haben eine eigendynamik.

dein unmut bringt keinem etwas! es nervt nur

c-ya mr.perfect